RxDoctor Payments Data

Oscar Maitas, MD

Interventional Cardiology · Seattle, WANPI 1386908531

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $14,304 of the $22,153 with a category attached, or 64.6%. 34 manufacturers reported payments, led by Abbott at 26.6% of the total.

$22,153in general payments, 2019–2025

Across 408 payments — averaging $54.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Edwards Lifesciences$4K
  • Biotronik Inc.$2K
  • Medtronic$1K
  • Johnson & Johnson$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$879
  • plus $7K from 28 others

What the payments were for

  • Travel & lodging$7,36833%
  • Food & beverage$14,30465%
  • Education$4812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,153 in reported general payments places this provider in the 80th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$7,847
Medicare patients
38
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate23$316

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →